Click Here to return To Results

 

The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator within 6 h of Acute Ischaemic Stroke (the third international stroke trial IST-3): a Randomised Controlled Trial Lancet 379: 2320, IST-3 collaborative group, 2012 See this aricle in Pubmed Article Abstract For the types of patient recruited in IST-3, despite the early hazards, thrombolysis within 6 h improved functional outcome. Benefit did not seem to be diminished in elderly patients.

Related Tags

(click to filter results - removes previous filter) cerebrovascular accident cerebrovascular accident,thrombolytic agents in treatment efficacy fibrinolytic agents fibrinolytic therapy,timing of administration prognosis safety tissue plasminogen activator,intravenous treatment of neurologic disorder

Click Here to return To Results